Literature DB >> 10755407

Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells.

V Speirs1, M J Kerin, D S Walton, C J Newton, S B Desai, S L Atkin.   

Abstract

Interleukin 6 (IL-6) is secreted by breast tumours and shows synergistic activity with 17beta-oestradiol (E2), leading to increases in reductive 17beta-hydroxysteroid dehydrogenase activity in breast cancer epithelial cells. However, the mechanisms involved are poorly understood. Using short-term epithelial cultures established from primary breast tumours, we have examined whether IL-6 could directly affect transcriptional activity of oestrogen reception alpha (ERalpha). Tumour epithelial cultures were established from 15 breast tumours, grown to 70% confluence and transiently transfected with a plasmid reporter containing the vitellogenin oestrogen response element and the luciferase coding sequence (ERE-TK-LUC). Following transfection, cells were incubated with E2, IL-6, the pure anti-oestrogen ZM 182780 or combinations of these substances for 48 h. Luciferase activity was then measured in cell lysates. E2 caused a dose-dependent increase in luciferase expression, causing a maximum threefold stimulation at 100 pM. In the presence of IL-6, transcriptional activity was increased by up to 2.5-fold in ERalpha+ cultures (11/15). In combination with E2, synergistic effects were observed with increases in luciferase activity of up to sixfold over controls. This effect could be blocked by treatment with ZM 182780. Pre-incubation of cells with an antibody directed against the signalling component of IL-6, gp130, was ineffective in blocking the E2 response. This antibody reduced, but did not completely block the effect of IL-6 either alone or in combination with E2, suggesting cross-talk between the two signalling pathways. In conclusion, these results provide evidence for direct transcriptional activation of ERalpha by IL-6.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755407      PMCID: PMC2374478          DOI: 10.1054/bjoc.1999.1097

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

Review 1.  Interleukin-6 and its receptor: a paradigm for cytokines.

Authors:  T Kishimoto; S Akira; T Taga
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

2.  Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha.

Authors:  P Pace; J Taylor; S Suntharalingam; R C Coombes; S Ali
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

3.  Estrogen receptors alpha and beta form heterodimers on DNA.

Authors:  S M Cowley; S Hoare; S Mosselman; M G Parker
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

4.  Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A.

Authors:  S Green; P Walter; V Kumar; A Krust; J M Bornert; P Argos; P Chambon
Journal:  Nature       Date:  1986 Mar 13-19       Impact factor: 49.962

5.  Sequence and expression of human estrogen receptor complementary DNA.

Authors:  G L Greene; P Gilna; M Waterfield; A Baker; Y Hort; J Shine
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

6.  Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.

Authors:  D Novick; L M Shulman; L Chen; M Revel
Journal:  Cytokine       Date:  1992-01       Impact factor: 3.861

7.  Interactive effects of interleukin-6, 17 beta-estradiol and progesterone on growth and 17 beta-hydroxysteroid dehydrogenase activity in human breast carcinoma cells.

Authors:  V Speirs; E F Adams; B Rafferty; M C White
Journal:  J Steroid Biochem Mol Biol       Date:  1993-07       Impact factor: 4.292

8.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture.

Authors:  Y Berthois; J A Katzenellenbogen; B S Katzenellenbogen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth.

Authors:  R B Dickson; M E McManaway; M E Lippman
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

10.  In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.

Authors:  V Speirs; D S Walton; M C Hall; S L Atkin
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

View more
  5 in total

Review 1.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

2.  Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations.

Authors:  Robynn V Schillace; Amy M Skinner; Rodney F Pommier; Steven O'Neill; Patrick J Muller; Arpana M Naik; Juliana E Hansen; SuEllen J Pommier
Journal:  BMC Cancer       Date:  2014-09-30       Impact factor: 4.430

3.  IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.

Authors:  Rasmus Siersbæk; Valentina Scabia; Sankari Nagarajan; Igor Chernukhin; Evangelia K Papachristou; Rebecca Broome; Simon J Johnston; Stacey E P Joosten; Andrew R Green; Sanjeev Kumar; Julia Jones; Soleilmane Omarjee; Ruben Alvarez-Fernandez; Silvia Glont; Sarah J Aitken; Kamal Kishore; Danya Cheeseman; Emad A Rakha; Clive D'Santos; Wilbert Zwart; Alasdair Russell; Cathrin Brisken; Jason S Carroll
Journal:  Cancer Cell       Date:  2020-07-16       Impact factor: 31.743

4.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.

Authors:  T Bachelot; I Ray-Coquard; C Menetrier-Caux; M Rastkha; A Duc; J-Y Blay
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

5.  Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.

Authors:  Adriana Papadimitropoulou; Luciano Vellon; Ella Atlas; Travis Vander Steen; Elisabet Cuyàs; Sara Verdura; Ingrid Espinoza; Javier A Menendez; Ruth Lupu
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.